- Home
- ABVX vs VSTM Comparison
ABVX vs VSTM Comparison
Compare ABVX & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVX
- VSTM
- Stock Information
- Founded
- ABVX 2013
- VSTM 2010
- Country
- ABVX France
- VSTM United States
- Employees
- ABVX N/A
- VSTM N/A
- Industry
- ABVX
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- ABVX
- VSTM Health Care
- Exchange
- ABVX Nasdaq
- VSTM Nasdaq
- Market Cap
- ABVX 511.3M
- VSTM 425.9M
- IPO Year
- ABVX N/A
- VSTM 2012
- Fundamental
- Price
- ABVX $66.49
- VSTM $6.14
- Analyst Decision
- ABVX Buy
- VSTM Strong Buy
- Analyst Count
- ABVX 7
- VSTM 9
- Target Price
- ABVX $65.71
- VSTM $12.63
- AVG Volume (30 Days)
- ABVX 2.8M
- VSTM 2.5M
- Earning Date
- ABVX 08-11-2025
- VSTM 08-07-2025
- Dividend Yield
- ABVX N/A
- VSTM N/A
- EPS Growth
- ABVX N/A
- VSTM N/A
- EPS
- ABVX N/A
- VSTM N/A
- Revenue
- ABVX $11,444,012.00
- VSTM $10,000,000.00
- Revenue This Year
- ABVX $284.20
- VSTM $81.24
- Revenue Next Year
- ABVX N/A
- VSTM $408.06
- P/E Ratio
- ABVX N/A
- VSTM N/A
- Revenue Growth
- ABVX 128.98
- VSTM N/A
- 52 Week Low
- ABVX $4.77
- VSTM $2.10
- 52 Week High
- ABVX $72.90
- VSTM $9.10
- Technical
- Relative Strength Index (RSI)
- ABVX 92.92
- VSTM 66.83
- Support Level
- ABVX $9.96
- VSTM $4.86
- Resistance Level
- ABVX $72.90
- VSTM $5.62
- Average True Range (ATR)
- ABVX 1.84
- VSTM 0.38
- MACD
- ABVX 6.88
- VSTM 0.18
- Stochastic Oscillator
- ABVX 90.17
- VSTM 91.23
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.